Abstract:
The present invention relates to a deuterated pyrrolo[2,3-b]pyridinyl compound that is useful for inhibiting Janus kinases. The invention also relates to processes and intermediates useful for preparing such a compound.
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
Abstract:
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
Abstract:
The present invention relates to a deuterated pyrrolo[2,3-b]pyridinyl compound that is useful for inhibiting Janus kinases. The invention also relates to processes and intermediates useful for preparing such a compound.
Abstract:
The present invention relates to compounds of formula I, wherein X, Q, W, R1, R2 and R3 are as defined in the claims, which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in, mammals. The present invention also relates to a method for preparing these compounds.
Abstract:
Un compuesto de fórmula I ** ver fórmula** o una de sus sales farmacéuticamente aceptables, en la que: W se selecciona de nitrógeno, CH o CF; X se selecciona de CH o CF; Z es O o NH; R1 es fenilo o un anillo heteroarilo de 5 a 6 miembros que tiene 1 a 3 heteroátomos seleccionados independientemente de oxígeno, nitrógeno o azufre, en el que: R1 está sustituido con 0-3 grupos seleccionados independientemente de -(T)y-Ar, R'', oxo, C(O)R'', CO2R'', OR'', N(R'')2, SR'', NO2, halógeno, CN, C(O)N(R'')2, NR''C(O)R'', SO2R'', SO2N(R'')2 o NR''SO2R''; y es 0 ó 1; T es una cadena alquilideno C1-4 lineal o ramificada, en la que una unidad metileno de T está opcionalmente reemplazada por -O-, -NH- o -S-; cada R'' se selecciona independientemente de hidrógeno, alifático C1-4, o un anillo saturado, insaturado de 5-6 miembros o arilo que tiene 0-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre, en el que: R'' está sustituido con 0-3 grupos seleccionados independientemente de halógeno, oxo, Rº, N(Rº)2, ORº, CO2Rº, NRºC(O)Rº, C(O)N(Rº)2, SO2Rº, SO2N(Rº)2 o NRºSO2Rº, en el que: cada Rº se selecciona independientemente de hidrógeno, alifático C1-4, o un anillo saturado, insaturado de 5-6 miembros o arilo que tiene 0-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre, y en el que: dos sustituyentes en posiciones adyacentes de R1 pueden tomarse juntos formando un anillo saturado, parcialmente insaturado de 5-7 miembros o arilo que tiene 0-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre; Ar es un anillo saturado, insaturado de 3-8 miembros o arilo, un anillo heterocíclico de 3-7 miembros que tiene 1-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre, o un anillo heteroarilo de 5-6 miembros que tiene 1-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre, en el que: Ar está sustituido con 0-3 grupos seleccionados independientemente de R'', oxo, CO2R'', OR'', N(R'')2, SR'', NO2, halógeno, CN, C(O)N(R'')2, NR''C(O)R'', SO2R'', C(O)R'', SO2N(R'')2 o NR''SO2R''; R2 se selecciona de hidrógeno o un grupo alifático C1-3; y El Anillo A es un anillo heteroarilo de 5-6 miembros que tiene 1-4 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre, con la condición de que dicho anillo tenga un aceptor de enlace de hidrógeno en la posición adyacente al punto de unión al Anillo B, en el que: el Anillo A está sustituido con 0-3 grupos seleccionados independientemente de R'', oxo, CO2R'', OR'', N(R'')2, SR'', NO2, halógeno, CN, C(O)N(R'')2, NR''C(O)R'', SO2R'', SO2N(R'')2 o NR''SO2R'', y en el que: dos sustituyentes en posiciones adyacentes del Anillo A pueden tomarse juntos formando un anillo saturado, parcialmente insaturado de 5-7 miembros o arilo que tiene 0-3 heteroátomos seleccionados independientemente de nitrógeno, oxígeno o azufre.
Abstract:
The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
Abstract:
The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.